Objective: To assess the safety and efficacy of early amino acid (AA) administration in preterm neonates <28 weeks gestational age.
Introduction
Postnatal growth restriction is reported to be almost universal among preterm infants. [1] [2] [3] [4] [5] Inadequate nutrient intake, cumulative energy and protein deficit in the initial days, severity of illness and concurrent administration of drugs (diuretics and steroids) are suspected in the pathogenesis of growth failure. 2, [5] [6] [7] The majority of energy and protein deficit occurs within the first two postnatal weeks. 5, 8 One of the mechanisms for poor growth in the initial days is delay in the initiation of total parenteral nutrition (TPN), especially protein and lipids after birth. Initiation of amino acid (AA) administration at 1.4-1.6g/kg/day immediately after birth and early administration of enteral feeds are the two most important strategies identified to reduce ongoing energy deficit and subsequent growth failure. 9 Development of hyperammonemia and metabolic acidosis was reported as concerns in early days of protein solutions administration to preterm neonates. 10, 11 However, with changes in the formulations and development of specific AA solutions, these concerns are being challenged. Randomized controlled studies 12, 13 using AA solutions immediately after birth revealed that this practice is not associated with these complications.
No differences were observed following early AA administration on short-term neonatal outcomes in a study of 32 preterm neonates of mean gestational age (GA) of approximately 27 weeks. 12 The number of infants evaluated to date to assess the safety and effectiveness of early TPN administration in extreme preterm neonates is small. The objective of this study was to assess the safety and efficacy of early AA administration in preterm neonates <28 weeks GA in association with a practice change. Safety of starting AA soon after birth was assessed by comparing incidence of clinically significant metabolic acidosis, uremia, acetate requirements in initial days and common neonatal outcomes of preterm infants. To evaluate efficacy, the days to regain birth weight, duration of TPN administration and growth profiles at 32 and 36 weeks corrected GA (CGA) were compared between late AA and early AA groups.
Materials and methods

Infants
This study was a prospective, comparative, observational study of infants admitted to the Neonatal Intensive Care Unit (NICU) at Mount Sinai Hospital, Toronto, Canada between March 2003 and April 2005. Preterm infants <28 weeks GA were enrolled after 2 weeks of age. Infants with congenital malformations, inborn errors of metabolism or chromosomal abnormalities were excluded. Parental consent was obtained at 2 weeks of age (in order not to overburden parents who were asked to participate in other interventional studies during first 2 weeks) to collect data from their infant during hospitalization to our hospital and if transferred to peripheral hospital from those hospitals before discharge home. Parents were not asked permission for administration of early AA administration, as it was a policy decision change of our NICU. The Research Ethics Board at Mount Sinai Hospital approved the study. GA was estimated from early dating ultrasound or maternal account of last menstrual period. All infants were managed in a servo-controlled thermoneutral environment until they were ready to be nursed in a crib or cot.
Procedure
Based on available studies at that time, a multidisciplinary decision to initiate administration of AA solution immediately after resuscitation was made in March 2003. In order to assess the effectiveness and safety of this approach, data were collected for infants treated with standard practice at that time (late AA group - Typically, the decision to start AA was made at next day's morning ward rounds and the infants received the solution late afternoon. Parenteral nutrition was started at 1.0 g/kg/day of AA (Primene Solutions, Baxter, Toronto, Canada) and 0.5-1.0 g/kg/day of 20% intralipid (Fresenius Kabi, Ab, Sweden). Both were advanced by 1.0 g/kg/day every 24 h if tolerated (in the absence of significant metabolic acidosis) to a maximum of 3.0-3.5 g/kg/day. Administration of glucose was initiated immediately after resuscitation and consisted of 10% dextrose solution, which was titrated as tolerated according to plasma glucose.
Early AA group. In April 2004, our parenteral nutrition protocol was changed to initiate AA solution in addition to the glucose solution in the resuscitation room (or as soon as the patient was stable) with the commencement goal of <6 h of age. A 2% AA solution (Primene Solutions, Baxter, Toronto, Canada) containing 10% dextrose was started at 80 cc/kg/day providing 1.4-1. 6 g/kg/ day depending on whether the infant had an umbilical arterial line (infused at rate of 0.5 cc/h). Lipids were started at similar times to the late AA group. Rate of advancement for AA and lipids were 1.0 g/kg/day with a maximum of 3.5-4 g/kg/day for AA and 3 g/kg/day for lipids. The dextrose concentration was titrated as tolerated according to plasma glucose.
The total fluid intake (TFI) per day remained similar in both groups during the study period. Acetate was added to TPN every day depending upon the degree of metabolic acidosis and was titrated every day. Enteral nutrition was started in both groups when possible (usually by day 2 or 3) and was advanced by 20 cc/kg/day to full enteral nutrition of 160 cc/kg/day. A similar policy for enteral nutrition was maintained throughout both study periods. Infants were fed either mother's expressed breast milk (EBM) or 20 kcal/oz preterm formula (Similac Special Care, Ross Products, Quebec, Canada). Human milk fortifier (Similac HMF, Ross Products, Quebec, Canada) was added to the EBM (1 packet to 25 cc of EBM) or the formula was switched to 24 kcal/oz (Similac Special Care, Ross Products, Quebec, Canada) at full enteral feeds. Target weight gain was 15 g/kg/day. If target weight gain was not achieved, human milk fortifier was increased to 1 packet per 20 cc of EBM if the TFI was p150 cc/kg/day or microlipids, a 50% fat emulsion which contains 100% safflower oil (Mead Johnson, Evansville, IN, USA) was added to supply an additional 10 kcal/ 100 cc. Human milk was assumed to contain 68 kcal/100 ml and 1.6 g/100 ml of protein at 4 weeks and 1.1 g/100 ml of protein at 8 weeks. Formula feeds and additives were prepared according to the manufacturer's specifications.
Data collection
Two dietitians (KK and ABT) prospectively collected data from blood tests results at 24 h of age for blood gas analysis, base excess, blood urea nitrogen, creatinine; type and amount of intravenous and/or enteral fluid intake; weight, length and head circumference at birth, at 28, 32 and 36 weeks CGA; use of medications (indomethacin, dexamethasone and diuretics); number of days to reach full enteral feedings; number of days and type of respiratory support; presence of patent ductus arteriosus; confirmed sepsis (identification of microorganism from either blood or cerebrospinal fluid in a symptomatic infant); chronic lung disease (defined as oxygen requirements at 36 weeks CGA); 14 necrotizing enterocolitis 15 and osteopenia of prematurity (defined as serum alkaline phosphatase >650 IU in patient without significant liver disease including TPN cholestasis). The length and head circumference data were measured by resident doctors looking after the infant. The weight data were compared with published reference standard for birth weight at specific GA for Canadian infants. 16 Significant hyperglycemia was defined as blood sugar >8 mmol/l in the presence of glycosuria. The infant was considered to have significant metabolic acidosis if the serum bicarbonate level was <18 and base deficit was >6.
Analysis
Data were analyzed using SPSS (Version 12, Chicago, IL, USA). Data from both groups of patients (late AA groups and early AA group) were compared by means of w 2 -test for categorical; Student's t-test and Wilcoxon sum test for continuous variables depending upon their distribution. A P-value p0.05 was considered significant. Data were collected for late AA group until all preparations were complete for early AA administration. A similar number of patients were enrolled in the early AA group for comparison. Post hoc power analysis revealed that to identify 2 days difference (s.d. of 4 days) in time to regain birth weight for a type 1 error of 0.05, this study had 73% power with 54 patients in each group (62 patients in each group needed for 80% power).
Results
During the study period between March 2003 to April 2005, a total of 252 neonates <28 weeks gestation were admitted to our NICU of whom 59 patients died before 2 weeks of age (31 in the late AA period and 28 in the early AA period). From the remaining 193 neonates, parents of 151 neonates were approached for consent (30 parents not available for approach, seven indicated not to be approached for any research, five were felt to be undergoing tremendous stress to be able to provide informed consent by attending team) for data collection, 91 parents (108 neonates; two sets of triplets and 13 sets of twins) agreed to participate. There was no difference in GA, sex and baseline severity of illness among 108 patients who participated and 85 who did not. There were 54 patients in each group. Five patients died; two in the late AA group (at 49 and 50 weeks CGA) and three in the early AA group (at 29, 31 and 38 weeks CGA) after enrollment in the study. Comparison of baseline demographic characteristics, time of administration of AA, days to regain birth weight and results of blood test carried out at 24 h of age between these two groups is reported in Table 1 . There was a statistically significant difference in the time of initiation of administration of AA between the two groups (mean difference 16 h; 95% confidence interval (CI) 14, 18 h). The number of days to regain the birth weight was of borderline significance (mean difference 2 days; 95% CI 0, 3 days). Three infants needed reduction in sugar intake owing to hyperglycemia/glucose intolerance in the early AA group compared to seven in the Table 2 . Incidences of common neonatal outcomes between groups are compared in Table 3 . There was statistically significant reduction in the number of infants with weight <10th centile at 32 weeks and number of infants with confirmed sepsis in the early AA group. None of the infants in either group developed significant TPN-induced cholestasis.
Discussion
In this prospective, observational, comparative (before-after) study, neonates in the early administration of AA group did not display clinically recognized adverse effects, and they regained birth weight 2 days earlier which indicates amelioration of early postnatal growth deficits. The neonates in early AA group had increases in blood urea, base deficit, acetate usage and reduced bicarbonate values; however, there was no statistically significant difference in number of infants with clinically important metabolic acidosis. The early AA group had marginally improved growth profile (number of infants with weight below 10th centile at 32 weeks CGA), and significantly reduced incidence of culture-proven sepsis.
Recently, safety and efficacy of early AA administration (at 2.4 g/ kg/day for first 5 days) in preterm neonates with a mean GA of 28.5 weeks (mean birth weight 1 kg) was evaluated in a randomized trial. 13 Higher urea and base deficit, and lower bicarbonate and pH values were identified when analyzed as a continuous measure similar to our study. We elected to start with intake of 1.4-1.6 g/kg/day as previous studies 17, 18 suggested that 1-1.5 g/kg/day was sufficient to prevent a catabolic state and prevent consequent growth deficit for extremely low birth weight infants. Additionally, we increased the infusion rate of AA to reach the recommended protein intake within 3 days of start of TPN. 19, 20 In our study, the early AA group received approximately 24 g/kg AA compared to approximately 18 g/kg AA (B25% less) received by the late AA group over the first week (at any given day, the patients in early group had 1-1.5 g/kg/day of higher AA intake compared Early amino-acid administration for preterm K Kotsopoulos et al to late group until both reached the maximum protein intake) and we suspect this to be the main reason for the earlier time to regain birth weight. However, simply providing excessive AA is not realistic owing to concerns of safety and tolerability. Cautious incremental increases of AA in the absence of significant side effects would be a preferable approach. The elevated urea levels in the early AA group in our study are similar to previously reported, 13 and reflects higher protein turnover and elevated oxidation of AA rather than toxicity. 21 Ibrahim et al. 12 in another randomized trial of 32 neonates administered AA at 3.5 g/kg/day within 2 h of birth and compared to AA started at 2 g/kg/day at 48 h of age. Early AA administration was well tolerated, resulted in positive nitrogen balance without significant impact on common outcomes of preterm infants. However, the number of patients studied is too small in both studies to detect significant difference in these outcomes. Other studies have reported 'early administration of AA'; 17, [21] [22] [23] [24] however, the intervention group in those studies were similar to the late AA groups in these studies 12, 13 and our study.
Postnatal malnutrition has been increasingly implicated not only with postnatal growth but also with neurodevelopmental outcomes and certain adult-onset diseases including diabetes mellitus and hypertension. 7,25 -29 Previous concerns of metabolic acidosis and hyperammonemia 10, 11 have been challenged in recent studies of improved AA formulations. 12, 21, 23, 24 However, a word of caution is warranted as our study and the study by Te Braake et al. 13 identified clinically unimportant but statistically significant differences in the values for pH, HCO 3 and base deficit indicative of metabolic acidosis. Overall, from a practical standpoint with the preparation of 'stock' solutions of 5, 7.5 and 10% dextrose and 2 g of AA/100 ml we are now able to initiate AA in the resuscitation room. The number of infants who developed hyperglycemia was lower in the early AA group compared to the late AA group, which may be owing to release of insulin following administration of certain AAs. 21, 30 There was a reduction in the incidence of sepsis which we speculate could be owing to improved nutritional status resulting in improved host defenses or probably owing to reduction in the number of days patient required intravenous access. No difference in other neonatal outcomes is encouraging; however, this needs to be monitored in future studies as there was a statistically insignificant increase in the number of infants with chronic lung disease and duration of respiratory support in the early AA group. We speculate that influx of high volume of intravenous protein may result in efflux of protein-rich material in the alveoli at a vulnerable time of extensive pulmonary inflammatory changes may aggravate damage resulting in severe chronic lung disease; however, this has not been shown in either human or animal studies. This finding needs to be monitored in further studies as well as by units who have changed their practices. We recognize that the sample size is small to detect any differences in all neonatal outcomes.
The strengths of our study include enrollment of especially vulnerable infants at lower GAs, shifting the AA administration curve to at least 24 h earlier, careful documentation of growth parameters at various postnatal ages and examination of the influence on neonatal outcomes to assess overall safety profile.
In the hierarchical model of evidence-based health care, randomized controlled trials are superior to other methodologies. However, based on mounting evidence from observational studies and certain randomized controlled studies, 21 ,23,24 a policy decision was made to adopt early AA practice in our unit making it difficult to perform a randomized trial. Thus, we elected to study this intervention in the next best scientific manner of pre-post study design. Limitations of such studies are potential bias of including patients with different severity of illness, and changes in management practices over time. There were no significant differences in the two study groups with respect to baseline characteristics including Clinical Risk Index for Babies scores at admission. To our knowledge, there has not been any major change in clinical practice that may have influenced outcome during the two periods; however, minor differences could not be ruled out. Long-term neurodevelopmental and growth outcomes are important and need to be studied to assess the safety of early AA administration.
In conclusion, our study is supporting the existing body of evidence of safety and advantages of early AA administration for preterm infants. With early AA administration, there were no clinically significant side effects in preterm infants <28 weeks gestation and time to regain birth weight was earlier. Future studies should carefully monitor acid-base status and respiratory status in this group of infants. Further studies assessing neurodevelopmental outcome and long-term effect on health of infants who received early AA are warranted.
